Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Hops (Humulus lupulus) contain bioactive prenylflavonoids—including xanthohumol, 8-prenylnaringenin (the most potent known phytoestrogen), and 6-prenylnaringenin—that modulate Nrf2 antioxidant signaling, inhibit NF-κB inflammatory cascades, and engage estrogen receptors to support sleep, hormonal balance, and neuroprotection. A 12-week randomized, double-blind, placebo-controlled trial (PMID 34399063) demonstrated that a standardized hop extract significantly reduced menopausal symptoms including hot flashes, while multiple pharmacological reviews confirm hops' sedative and anxiolytic efficacy through GABAergic modulation (PMID 34116572; PMID 38025741).
Reported Benefits (Provisional)
Origin & History
Hops (Humulus lupulus) are the cone-shaped flowers of a perennial vine native to Europe, Asia, and North America, thriving in temperate climates. Best known for their role in brewing, hops have a long history in traditional herbal medicine, valued for their calming, sedative, and digestive properties. Their therapeutic effects stem from a rich array of bitter acids, flavonoids, and volatile oils, making them relevant for relaxation, metabolic health, and cognitive well-being.
Research Narrative (Provisional)
A 12-week multicenter, randomized, double-blind, placebo-controlled clinical trial published in the Journal of Alternative and Complementary Medicine (Kim HI et al., 2021; PMID 34399063) found that a standardized soy and hop extract significantly improved menopausal symptoms including hot flashes and sleep disturbances compared to placebo. A comprehensive review in Pharmacological Reviews (Dietz BM et al., 2016; PMID 27677719) characterized 8-prenylnaringenin from hops as the most potent phytoestrogen identified from plants, detailing its selective estrogen receptor binding and implications for women's health. An updated systematic review in Planta Medica (Borrás S et al., 2021; PMID 34116572) confirmed hops' efficacy for insomnia related to anxiety, particularly when combined with valerian, citing improvements in sleep latency and quality. A 2023 pharmacokinetic review in PeerJ (Czigle S et al.; PMID 38025741) documented hops' CNS-active mechanisms and potential herb-drug interactions involving GABAergic pathways and CYP450 enzyme modulation.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Bioactives: Humulone, lupulone, xanthohumol (sedative, anti-inflammatory, neuroprotective) - Phytochemicals: Phytoestrogens (hormonal support), polyphenols, flavonoids (immune, cellular protection, anti-anxiety) - Volatile Oils: Myrcene (sedative, calming properties) - Minerals: Trace amounts of magnesium, potassium (nerve function, muscle relaxation)
Reported Mechanism (Provisional)
Xanthohumol, the principal prenylated chalcone in hops, activates the Keap1-Nrf2 signaling pathway, upregulating phase II detoxification enzymes including NAD(P)H quinone oxidoreductase 1 (NQO1) and glutathione S-transferase (GST), while concurrently suppressing NF-κB and Akt inflammatory signaling cascades (PMID 27677719). 8-Prenylnaringenin functions as the most potent plant-derived phytoestrogen, binding selectively to estrogen receptor-alpha (ERα) with an affinity exceeding that of other dietary isoflavones, thereby modulating estrogenic gene expression relevant to menopausal symptom relief (PMID 27677719; PMID 34946512). 6-Prenylnaringenin acts as an aryl hydrocarbon receptor (AhR) agonist, upregulating cytochrome P450 1A1 (CYP1A1) to facilitate estrogen hydroxylation and detoxification. The bitter acids (alpha-acids humulone and beta-acids lupulone) and the degradation product 2-methyl-3-buten-2-ol enhance GABAergic neurotransmission by positively modulating GABA-A receptors, accounting for hops' clinically observed sedative and anxiolytic effects (PMID 34116572; PMID 17555057).
Clinical Narrative (Provisional)
Current evidence is primarily derived from in vitro and animal studies rather than robust human clinical trials. RT-qPCR analysis in MCF-10A and MCF-7 cell lines demonstrated significant CYP1A1 enzyme induction by 6-prenylnaringenin. ORAC antioxidant assays identified gallic acid (SC50 8.5 μM), procyanidin B3 (7.6 μM), and quercetin (8.6 μM) as the most potent radical scavengers among hop phenolic compounds. Human clinical trials with specific efficacy metrics and quantified outcomes are notably lacking in current literature.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.